US/UK/Canada

Share

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.

Pick a time period -
Tags ( Active)

Meda Aktiebolag successfully amends MTN terms and conditions and exercises call option

Meda Aktiebolag has successfully amended the terms and conditions of two series of notes issued pursuant to its SEK 7,000,000,000 medium term notes programme and inserted an early redemption call option which it will exercise with immediate effectToday, Meda Aktiebolag (the “Company”) held two noteholders’ meetings pursuant to the summons sent on 7 November 2017 to the noteholders of the: (i) SE0005132180 – STIBOR 3M +2.85% 2013/2018 notes (the “2018 Notes”); and (ii) SE0005991635 – STIBOR 3M +1.65% 2014/2019 notes (the “2019 Notes” and together, with the 2018 Notes, the “Notes”),

Meda Aktiebolag summons noteholders’ meetings

Meda Aktiebolag summons noteholders’ meetings for the purposes of approving the insertion of an early redemption call option into the terms and conditions of two series of notes issued pursuant to its SEK 7,000,000,000 medium term notes programmeMylan N.V., the parent of the Company, is consolidating debt in acquired entities to Mylan N.V. in order to optimise its overall debt profile. Therefore, today, Meda Aktiebolag (the “Company”) has summoned noteholders’ meetings to take place on 6 December 2017 at 09:00 hours (CET) and 09:30 hours (CET) respectively in respect of the: (i)

Information to the holders of notes issued by Meda

Meda AB has previously issued 2013/2018 SEK 600,000,000 floating rate notes (ISIN: SE0005132180) and 2014/2019 SEK 750,000,000 floating rate notes (ISIN: SE0005991635), which are traded on Nasdaq Stockholm (the “Notes”). Following the completion of a public tender offer by Mylan N.V. (“Mylan”) regarding Meda in August 2016, Meda is now a Mylan subsidiary. The shares of Mylan are listed on the NASDAQ Global Select Stock Market in the United States and the Tel Aviv Stock Exchange in Israel. Mylan has issued a guarantee in favor of each of the holders of the Notes (the “Guarantee”).

Bulletin from the extraordinary general meeting in Meda AB (publ)

At the extraordinary general meeting held today, 25 August, 2016, Meda AB (publ) resolved that the board shall, for the period until the end of the next Annual General Meeting, consist of Caroline Dixon, Jacek Glinka and Colleen Ostrowski, with Jacek Glinka as Chairman of the board. For further inquiries, please contact: Paula Treutiger, VP Corporate Communications & Sustainability                                     ph: +46 733-666 599

Notice to noteholders regarding change of control

Following the public tender offer to the shareholders of Meda AB (publ) (the “Issuer”) as of 10 February, 2016, Mylan N.V. (“Mylan”) has as per 5 August 2016 confirmed it has become owner of approximately 94 per cent of the shares and votes in the Issuer. The acquisition of the shares in the Issuer by Mylan constitutes a change of control event as further described in the terms and conditions for each of the 2013/2018 SEK 600,000,000 Floating Rate Notes (ISIN: SE0005132180) and 2014/2019 SEK 750,000,000 Floating Rate Notes (ISIN: SE0005991635) issued by the Issuer (collectively the “Notes”).

Mylan Completes Acquisition of Meda

HERTFORDSHIRE, England, and PITTSBURGH, Aug. 5, 2016 -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has completed the settlement of its recommended public offer to the shareholders of Meda Aktiebolag (publ.) to tender all their shares in Meda to Mylan (the “Offer”). As previously announced, the Offer was accepted by shareholders holding approximately 94% of the total number of outstanding shares and votes in Meda, as of July 29, 2016. Upon the completion and settlement of the Offer, Mylan acquired each of these shares in accordance with the terms of the Offer. The Offer was

Meda Aktiebolag (publ) applies for delisting and convenes an extraordinary general meeting

Mylan N.V.s public offer for Meda Aktiebolag (publ) (“Meda”) was declared unconditional today on August 2, 2016. Mylan N.V. controls more than 90 per cent of the shares in Meda and intends to request compulsory acquisition in respect of the shares in Meda that Mylan N.V. does not own. As requested by Mylan N.V., the Board of Meda has today convened an Extraordinary General Meeting to be held on August 25, 2016, for the purposes of, amongst other things, appointing a new board. Further, at the request of Mylan N.V. the Board of Meda has resolved to apply for delisting of the Company’s

Extraordinary General Meeting of Meda Aktiebolag (publ)

At the request of Mylan N.V., which after completion of its public offer to the shareholders of Meda Aktiebolag (“Meda” or the “Company”) owns more than nine-tenths of the shares in Meda, the shareholders of Meda are hereby invited to attend the Extraordinary General Meeting on Thursday August 25, 2016 at 3 p.m. on Meda’s premises at Pipers väg 2A, Solna, Sweden. Right to participate Shareholders who wish to participate shall: both               be registered in the share register held by Euroclear Sweden AB on Friday August                       19 2016, and and

Interim Report, January-June 2016

January-June 2016 ·  Net sales reached SEK 9,330 million (9,735), corresponding to a decrease of 4% and a flat organic sales development compared with the previous year. ·  EBITDA, excluding non-recurring items, was SEK 2,832 million (3,183), corresponding to a margin of 30.4% (32.7). ·  Non-recurring items related to the Mylan offer had a SEK 309 million negative impact on earnings before tax. ·  Profit after tax amounted to SEK 589 million (618). ·  Earnings per share reached SEK 1.61 (1.69). Excluding non-recurring items, earnings per share totaled SEK 1.65 (1.93). ·

Meda’s second quarter 2016 report

Meda will publish its second quarter results on Thursday, 21 July 2016 at 8:00 CET. For further inquiries, please contact: Paula Treutiger, VP Corporate Communications & Sustainability                                     ph: +46 733-666 599                                                                                                                                                                                                                  paula.treutiger@meda.se MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in more than 150

Interim Report, January-March 2016

January-March 2016 · Net sales reached SEK 4,315 million (4,583), corresponding to a decrease of 6% and an organic sales development of -2%, compared with the previous year. · EBITDA, excluding non-recurring items, was SEK 1,256 million (1,403), corresponding to a margin of 29.1% (30.6). · Non-recurring items related to the Mylan offer had a SEK 121 million negative impact on earnings before tax. · Profit after tax amounted to SEK 291 million (226). · Earnings per share reached SEK 0.80 (0.62). Excluding non-recurring items, earnings per share totaled SEK 0.46 (0.59). ·

Invitation to teleconference for analysts, investors and media

Presentation of Meda’s First Quarter Results 2016On Tuesday, May 3rd, 2016 at 8:00 CET, Meda will release its First Quarter Results for 2016. Meda invites all analysts, investors and media to a teleconference to be held on Tuesday,   May 3rd at 10:00 CET!During the teleconference, CEO Jörg-Thomas Dierks and CFO Henrik Stenqvist will present the 2016 First Quarter report.The First Quarter report will be available at Meda’s website, www.meda.se. Slides from the presentation will be available at the same address. The webcast presentation can be heard at:http://edge.media-server.com/m/p/

Meda AB (publ) AGM bulletin

At the annual general meeting (AGM) on April 14, 2016, of Meda AB (publ), an unchanged dividend of 2.50 SEK per share was declared. The AGM adopted balance sheets and income statements and discharged the members of the board and the CEO from liability. Further, the AGM resolved to adopt the nomination committee’s proposal for remuneration to the board and the auditors. The board was elected according to the nomination committee´s proposal. The AGM also resolved to elect auditor in accordance with the nomination committee’s proposal. The AGM also authorized the board to make

Mylan to present at Meda’s Annual General Meeting

Robert J. Coury, Executive Chairman Mylan, and Heather Bresch, CEO Mylan, will provide a presentation of Mylan in connection with Meda’s Annual General Meeting (AGM). The AGM will be held at 5.00 PM on Thursday, April 14, 2016, at Meda’s headquarters at Pipers väg 2A, Solna, Sweden. For further inquiries, please contact:                             Paula Treutiger, VP Corporate Communications & Sustainability                                     ph: +46 733-666 599

Meda’s annual report is published

Meda has today published its annual report for 2015 on www.meda.se. The printed version will be distributed to shareholders later in April. For further inquiries, please contact: Paula Treutiger, VP Corporate Communications & Sustainability                                     ph: +46 733-666 599            paula.treutiger@meda.se Meda AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on March 24, 2016, at 10:00 CET. MEDA AB (publ) is a leading

NOTICE OF ANNUAL GENERAL MEETING IN MEDA AB (publ)

Notice is hereby given to the shareholders of Meda AB (publ), corp.reg.no 556427-2812, that the Annual General Meeting (AGM) will be held at 5.00 PM on Thursday, April 14, 2016, at Meda’s headquarters at Pipers väg 2A, Solna, Sweden. Registration starts at 4.00 PM. Right to participate Shareholders who wish to participate in the AGM shall: ·be registered in the share register held by Euroclear Sweden AB on Friday, April 8, 2016, and ·send notice of their intention to participate in the AGM to Meda by Friday, April 8, 2016. In order to be entitled to vote at the AGM,

Year-end Report, January-December 2015

January-December 2015[1] · Net sales reached SEK 19,648 million (15,352), corresponding to an increase of 28%, 21% at constant exchange rates, compared with the previous year. · EBITDA, excluding non-recurring items, was SEK 6,482 million (4,700), corresponding to an increase of 38%, and a margin of 33.0% (30.6). · Non-recurring items had a SEK 698 million negative impact on earnings before tax. · Profit after tax amounted to SEK 1.192 million (402). · Earnings per share reached SEK 3.22 (1.23)[2]. Excluding non-recurring items, earnings per share totaled SEK 4.14 (3.64)[2].

Statement by the Board of Directors of Meda in relation to the public offer by Mylan

The Board of Directors of Meda unanimously recommends that the shareholders of Meda accept the offer made by MylanBackground This statement is made by the Board of Directors (the “Board”) of Meda AB (publ.) (“Meda” or the “Company”) pursuant to Section II.19 of Nasdaq Stockholm’s Takeover Rules (the “Takeover Rules”). Mylan N.V., a leading global pharmaceutical company whose ordinary shares (“Mylan Shares”) are traded on the NASDAQ Global Select Market and the Tel Aviv Stock Exchange under the symbol “MYL”, has today announced a public offer to the shareholders of Meda to transfer all

Invitation to teleconference for analysts, investors and media

Presentation of Meda’s Year-End Results 2015On Thursday, February 11th , 2016 at 8:00 CET, Meda will release its Year-End Results for 2015. Meda invites all analysts, investors and media to a teleconference to be held on Thursday, February 11th at 10:00 CET!During the teleconference, CEO Jörg-Thomas Dierks and CFO Henrik Stenqvist will present the 2015 Year-End report.The Year-End report will be available at Meda’s website, www.meda.se. Slides from the presentation will be available at the same address. The webcast presentation can be heard at:http://edge.media-server.com/m/p/dzbbgz3x

Divestment of manufacturing unit Euromed in Spain completed

On December 1st, 2015, Meda announced the divestment of the manufacturing unit Euromed in Spain. The divestment has now been completed. The total consideration is EUR 82 million in upfront cash for the shares of Euromed. The unit generates sales of around EUR 40 million and an EBITDA margin of around 20% on an annual basis. For further inquiries, please contact: Paula Treutiger, VP Corporate Communications & Sustainability                                     ph: +46 733-666 599

Meda divests manufacturing unit Euromed in Spain

Meda has entered into a definitive agreement with The Riverside Company (“Riverside”) for the sale of Euromed S.A. (“Euromed”), a business-to-business manufacturer of herbal extracts and natural active substances located in Spain. The total consideration is EUR 82 million in upfront cash for the shares of Euromed. The unit generates sales of around EUR 40 million and an EBITDA margin of around 20% on an annual basis. Euromed is a legacy Rottapharm subsidiary, now part of Meda, and has historically been the supplier of the key Legalon API. Meda and Riverside have entered into a favorable

Update on license agreement between Meda and Valeant

Meda out-licensed its dermatological products Elidel and Xerese to Valeant in North America in 2011. Elidel is a patented prescription product for the treatment of atopic dermatitis. The license agreement followed a decision by Meda to focus on the Respiratory area with its sales force in the US. Meda is entitled to royalties based on net sales of these products and Zovirax. For 2015 the royalties amount to USD 40 million, less than 2% of Meda’s expected net sales. For 2016 and onwards the agreement stipulates lower royalties for Meda, for the next year expected to be about half the amount

There are no items matching the current filter
There are no more items matching the current filter
Back to top